866-997-4948 (US-Canada Toll Free)

Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM

Published By :

GBI Research

Published Date : 2014-08-21

Category :

Therapeutic Area

No. of Pages : N/A

Product Synopsis

GBI Research, the leading business intelligence provider, has released its latest research: ‘Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM’, which provides in-depth analysis of the Glioblastoma Multiforme (GBM) therapeutics market within the Asia-Pacific (APAC) region, covering Australia, China, India and Japan. The report provides estimates of market size for 2013, along with market forecasts until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, and in-depth analysis of the marketed and pipeline products. The value of the GBM market in the APAC region amounted to an estimated $49.4m in 2013, and is expected to register a... Read More

Table Of Content

Table of Content

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 – Introduction
2.1 Disease Introduction
2.2 Classification of Brain Tumors
2.3 Tumor Grading
2.4 Subtypes of Glioblastoma Multiforme
2.5 Etiology
2.6 Pathophysiology
2.6.1 Loss of Heterozygosity of Chromosome 10
2.6.2 Epidermal Growth Factor Receptor Amplification
2.6.3 Phosphatase and Tensin Homolog Mutation
2.6.4 Loss of p53 Function
2.6.5 p16INK4a Alteration and Loss of Normal Retinoblastoma 1 Function
2.6.6 Isocitrate Dehydrogenase 1 or Isocitrate Dehydrogenase 2 Mutation
2.7 Symptoms
2.8 Diagnosis
2.9 Prognosis
2.10 Epidemiology
2.11 Treatment Options
2.11.1 Surgery
2.11.2 Radiation Therapy
2.11.3 Chemotherapy
2.11.4 Targeted Therapy
2.11.5 Drugs for Symptom Relief
2.11.6 Other Alternative Therapies
2.12 Treatment Algorithm
2.13 GBI Research Report Guidance

3 Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 – Marketed Products
3.1 Key Marketed Products
3.2 Temodar (temozolomide) – Merck
3.3 Avastin (bevacizumab) – Roche
3.4 BiCNU (carmustine) and Gliadel Wafer (carmustine in polifeprosan)
3.4.1 BiCNU (carmustine) – Bristol-Myers Squibb
3.4.2 Gliadel Wafer (carmustine in polifeprosan) – Eisai
3.5 Unlicensed/Off-Label Use in Glioblastoma Multiforme
3.5.1 Lomustine
3.5.2 Carboplatin
3.5.3 Teniposide
3.6 Comparative Efficacy and Safety
3.7 Unmet Needs

4 Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 – Pipeline
4.1 Overall Pipeline
4.2 Molecular Targets
4.3 Clinical Trials
4.3.1 Clinical Trial Size
4.3.2 Clinical Trial Duration
4.3.3 Failure Rate of Developmental Pipeline
4.3.4 Summary of Clinical Trial and Risk Analysis
4.4 Promising Pipeline Candidates
4.4.1 Rindopepimut (CDX-110) – Celldex Therapeutics
4.4.2 Avastin (bevacizumab) – Roche
4.4.3 Cotara – Peregrine Pharmaceuticals
4.4.4 BIOMAb (nimotuzumab) – BioCon
4.5 Heat Map of Safety and Efficacy and Product Competitiveness Framework for Glioblastoma Multiforme Pipeline

5 Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 – Market Forecast to 2020
5.1 Asia-Pacific Market
5.1.1 Treatment Use Patterns
5.1.2 Market Size
5.2 Australia
5.2.1 Treatment Use Patterns
5.2.2 Annual Cost of Therapy
5.2.3 Market Size
5.3 China
5.3.1 Treatment Use Patterns
5.3.2 Annual Cost of Therapy
5.3.3 Market Size
5.4 India
5.4.1 Treatment Use Patterns
5.4.2 Annual Cost of Therapy
5.4.3 Market Size
5.5 Japan
5.5.1 Treatment Use Patterns
5.5.2 Annual Cost of Therapy
5.5.3 Market Size
5.6 Drivers and Barriers for the Glioblastoma Multiforme Therapeutics in the Asia-Pacific Market to 2020
5.6.1 Drivers
5.6.2 Barriers

6 Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 – Deals and Strategic Consolidations
6.1 Major Co-Development Deals
6.1.1 Del Mar Pharmaceuticals Enters into Agreement with Guangxi Wuzhou Pharmaceutical
6.1.2 Immatics Biotechnologies Enters into Agreement with Cancer Research UK
6.2 Major Licensing Deals
6.2.1 Eisai Received Marketing Authorization Holder License with Nobelpharma for Gliadel in Japan
6.2.2 Teva Pharma Enters into Agreement with Perrigo for Generic Temozolomide
6.2.3 SOM Biotech Enters into Licensing Agreement with Argon Pharma for SOM0777
6.2.4 ImmunoCellular Therapeutics Enters into Agreement with University of Pennsylvania
6.2.5 Bexion Pharmaceuticals Enters into Agreement with Cincinnati Children’s Hospital Medical Center
6.2.6 Celldex Therapeutics Enters into Agreement with Duke University Brain Tumor Cancer Center

7 Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 – Appendix
7.1 Market Definitions
7.2 Abbreviations
7.3 Bibliography
7.4 All Pipeline Products by Phase
7.4.1 Discovery
7.4.2 Preclinical
7.4.3 Phase I
7.4.4 Phase II
7.4.5 Phase III and Pre-Registration
7.4.6 Undisclosed stage of development
7.5 Market Forecasts to 2020
7.5.1 Asia-Pacific
7.5.2 Australia
7.5.3 China
7.5.4 India
7.5.5 Japan
7.6 Research Methodology
7.6.1 Coverage
7.6.2 Secondary Research
7.6.3 Therapeutic Landscape
7.6.4 Forecasting
7.6.5 Geographical Landscape
7.6.6 Pipeline Analysis
7.7 Competitive Landscape
7.8 Expert Panel Validation
7.9 Contact Us
7.10 Disclaimer

List of Tables

Table 1: Glioblastoma Multiforme, Classification of Brain Tumors by the American Association of Neurological Surgeons, 2014
Table 2: Glioblastoma Multiforme, World Health Organization Classification of Glioma, 2005
Table 3: Glioblastoma Multiforme, Karnofsky Performance Status Score (%), 1984
Table 4: Discovery
Table 5: Preclinical and IND/CTA-filed
Table 6: Phase I
Table 7: Phase II
Table 8: Phase III and pre-registration
Table 9: Undisclosed stage of development
Table 10: Glioblastoma Multiforme Therapeutics, Asia-Pacific, Forecast Data, 2013–2020
Table 11: Glioblastoma Multiforme Therapeutics, Australia, Forecast Data, 2013–2020
Table 12: Glioblastoma Multiforme Therapeutics, China, Forecast Data, 2013–2020
Table 13: Glioblastoma Multiforme Therapeutics, India, Forecast Data, 2013–2020
Table 14: Glioblastoma Multiforme Therapeutics, Japan, Forecast Data, 2013–2020

List of Figures

Figure 1: Glioblastoma Multiforme, Genetic Pathways to Primary and Secondary GBM and the Incidence of Mutations, 2014
Figure 2: Glioblastoma Multiforme, Treatment Algorithm for Glioblastoma Multiforme, 2014
Figure 3: Glioblastoma Multiforme, Treatment Options for Recurrent Glioblastoma Multiforme, 2014
Figure 4: Glioblastoma Multiforme, Global, Historical Sales of Temodar ($m), 2008–2013
Figure 5: Glioblastoma Multiforme, Global, Historical Sales of Avastin ($bn), 2004–2013
Figure 6: Glioblastoma Multiforme, Global, Historical Sales of Gliadel Wafer ($m), 2003–2006
Figure 7: Glioblastoma Multiforme , Global, Heat Map for Marketed Products, 2013
Figure 8: Glioblastoma Multiforme, Global, Overall Pipeline, 2013
Figure 9: Glioblastoma Multiforme, Global, Program Type by Phase and Molecular Targets, 2013
Figure 10: Glioblastoma Multiforme, Global, Mean Clinical Trial Size by Molecule Type, 2006–2013
Figure 11: Glioblastoma Multiforme, Global, Mean Clinical Trial Duration by Molecule Type (Months), 2006–2013
Figure 12: Glioblastoma Multiforme, Global, Clinical Trial Failure Rate by Phase by Molecule Type and Reasons for Failure, 2006–2013
Figure 13: Glioblastoma Multiforme, Asia-Pacific, Heat Map for Pipeline Products, 2013
Figure 14: Glioblastoma Multiforme, Asia-Pacific, Product Competitiveness Framework, 2013
Figure 15: Glioblastoma Multiforme Therapeutics, Asia-Pacific, Treatment Use Patterns (‘000), 2013–2020
Figure 16: Glioblastoma Multiforme Therapeutics, Asia-Pacific, Market Size ($m), 2013–2020
Figure 17: Glioblastoma Multiforme Therapeutics, Australia, Treatment Use Patterns (‘000), 2013–2020
Figure 18: Glioblastoma Multiforme Therapeutics, Australia, Annual Cost of Therapy ($), 2013–2020
Figure 19: Glioblastoma Multiforme Therapeutics, Australia, Market Size ($m), 2013–2020
Figure 20: Glioblastoma Multiforme Therapeutics, China, Treatment Use Patterns (‘000), 2013–2020
Figure 21: Glioblastoma Multiforme Therapeutics, China, Annual Cost of Therapy ($), 2013–2020
Figure 22: Glioblastoma Multiforme Therapeutics, China, Market Size ($m), 2013–2020
Figure 23: Glioblastoma Multiforme Therapeutics, India, Treatment Use Patterns (‘000), 2013–2020
Figure 24: Glioblastoma Multiforme Therapeutics, India, Annual Cost of Therapy ($), 2013–2020
Figure 25: Glioblastoma Multiforme Therapeutics, India, Market Size ($m), 2013–2020
Figure 26: Glioblastoma Multiforme Therapeutics, Japan, Treatment Use Patterns (‘000), 2013–2020
Figure 27: Glioblastoma Multiforme Therapeutics, Japan, Annual Cost of Therapy ($), 2013–2020
Figure 28: Glioblastoma Multiforme Therapeutics, Japan, Market Size ($m), 2013–2020

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *

Upcoming Reports

  • Greece: underwear market

    By - Williams and Marshal Strategy

    This report presents a comprehensive overview of the underwear market in Greece and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the underwear market in Greece, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate overview of the main...

  • Satellite-Based Earth Observation Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast 2014 - 2020

    By - Transparency

    Satellite-based Earth Observation (EO) is a process of using remote-sensing technique to gather information on the chemical, physical and biological aspects of the earth system. This technique allows the measurement of geophysical parameters of the earth from the orbit with the use of cameras and sensors. The gathered information can be effectively used to monitor and predict cloud cover and climate patterns, detect and assess damage during floods, tsunamis, and other natural disasters, agricultural and usage, petroleum and mineral deposits, availability of water sources. It also...

  • Methanol Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2012 - 2018

    By - Transparency

    Methanol is the liquefied form of methane, a gas which is usually produced as a result of the decomposition of organic matter. Methanol is one of the better alternatives available for contemporary gasoline products as it dispenses the same amount of energy. It also acts as an additive in petroleum products, boosting the performance of internal combustion engines. Methanol is also called methyl alcohol or wood alcohol and is naturally found in volcanic gases and wood. Some of the major factors driving the global methanol market include efficiency of plants in producing the gas,...